Navigation Links
Bionovo Reports on Metabolic Studies Related to Its Menopausal Hot Flash Drug Candidate
Date:9/12/2008

EMERYVILLE, Calif., Sept. 12 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: BNVI) today announced the publishing of a paper in the journal for the American Society for Pharmacology and Experimental Therapeutics, Drug Metabolism and Disposition, entitled "Oxidative In Vitro Metabolism of Liquiritigenin, a Bioactive Compound Isolated from the Chinese Herbal Selective Estrogen Beta-Receptor Agonist MF101."

Liquiritigenin is one of the active compounds of MF101, Bionovo's drug candidate for the treatment of menopausal hot flashes, currently poised to start Phase 3 clinical testing.

The paper describes in vitro metabolism of Liquiritigenin which is almost exclusively metabolized by cytochrome P450 3A4. The metabolite that was identified is three times more potent than the parent compound towards selective activation of the estrogen receptor beta. Enzyme kinetic experiments suggest that clinically relevant drug-drug interactions are highly unlikely, which is a positive safety feature of MF101, applicable if the drug is taken in combination with other drugs.

The paper is available at http://dmd.aspetjournals.org/cgi/reprint/dmd.108.021402v1.

"Most adverse drug reactions are linked to metabolism of the drug in the human body. Many women of menopausal age may be simultaneously taking other drugs for various indications. Our study shows that the metabolism of a major active compound of MF101 will most likely not adversely interact with other drugs. It also results in the production of an even more potent estrogen receptor beta agonist potentially enhancing the clinical efficacy. The results of this study mark a critical milestone in our mission to develop truly safe and effective treatments for significant unmet medical needs in women's health," said Dr. Isaac Cohen, Bionovo's chairman and CEO.

Bionovo, Inc.

Bionovo is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, markets with significant unmet needs and billions in potential annual revenue. The company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources which have novel mechanisms of action. Based on the results of early and mid-stage clinical trials, Bionovo believes they have discovered new classes of drug candidates within their rich pipeline with the potential to be leaders in their markets. Bionovo is headquartered in Emeryville, California and is traded on the NASDAQ Capital Market under the symbol, "BNVI". For more information about Bionovo and its programs, visit http://www.bionovo.com.

Forward Looking Statements

This release contains certain forward-looking statements relating to the business of Bionovo, Inc. that can be identified by the use of forward-looking terminology such as "believes," "expects," or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including uncertainties relating to product development, efficacy and safety, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, market acceptance, physician acceptance, third party reimbursement, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Certain of these risks and uncertainties are or will be described in greater detail in our filings with the Securities and Exchange Commission, which are available at http://www.sec.gov. Bionovo, Inc. is under no obligation (and expressly disclaims any such obligation) to update or alter its forward-looking statements whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Bionovo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Bionovo Announces Positive Developments in On-going Phase 1/2 Cancer Drug Trial
2. Bionovo Announces Publication of the Paper Detailing the Mechanism of Action of Its Cancer Drug BZL101
3. Bionovo Discovers New Estrogen Regulatory Elements for Breast Cancer and Osteoporosis Drugs
4. Bionovos Drug Candidate for Menopausal Symptoms Shows Effect on Neural Pathways Related to Temperature Regulation
5. Bionovo Elucidates Mechanism of Breast Cancer Control by Estrogen Receptor Beta
6. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
7. Spherix Reports Second Quarter Earnings
8. Tapestry Reports Second Quarter 2007 Results
9. Callisto Reports on Second-Quarter 2007 Milestones
10. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
11. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... 27, 2017  Market Research presents an all-encompassing and one ... market titled ,Medical Fiber Optics Market: Global Industry Analysis and ... globally across the five key regions of North ... Europe , APAC and MEA which influence the ... optics market over the forecast period. In this report, Persistence ...
(Date:2/28/2017)... TRIANGLE PARK, N.C. , Feb. 28, 2017 ... that Martine Rothblatt , Ph.D., Chairman and Chief Executive ... on the company,s business at the Cowen and Company 37 ... Massachusetts . The presentation will take place ... and can be accessed via a live webcast on the ...
(Date:2/28/2017)... 27, 2017  Clarivate Analytics marks the passing of one if its ... contributions to information science in the service of scientific and scholarly research. ... an indexing system that revolutionized the way researchers work with the literature, ... Continue Reading ... ...
Breaking Medicine Technology:
(Date:2/27/2017)... ... 27, 2017 , ... Much attention has been paid to the problem of ... opioid painkillers has fallen short. From 1999 until 2010, fatal overdoses from prescription pain ... overdoses in male populations.(1) , The proportion of women using illicit drugs is also ...
(Date:2/27/2017)... ... 2017 , ... Elisa Guajardo Carothers is not your typical author. She went from working as ... Now, she writes about God, when she isn’t swimming as a performing mermaid. , Her ... BS! (Before Satan),” she offers a comedic look at the dysfunctions of God’s family, before ...
(Date:2/27/2017)... ... February 27, 2017 , ... ... on laser diffraction analysis as a tool to characterize particle size distributions in ... to obtain improved results and novel scientific findings. It describes methods of optimized ...
(Date:2/27/2017)... POUGHKEEPSIE, N. Y. (PRWEB) , ... February 27, 2017 , ... ... Society ( ILADS ) has disclosed that despite scientific studies, the Center for Disease ... of chronic Lyme disease . Kenneth B. Liegner, M.D. has compiled into ...
(Date:2/27/2017)... , ... February 27, 2017 , ... ... and alcohol treatment programs in British Columbia, Canada, at https://www.sunshinecoasthealthcentre.ca/ , is ... team. The new hire, Mackenzie Alsager, showcases the Centre's commitment to innovation in ...
Breaking Medicine News(10 mins):